Trial
NCT03864627
A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Participants With Moderate to Severe Atopic Dermatitis
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Lakefront Biotherapeutics NV
Collaborators
—
Condition
Atopic Dermatitis
Intervention
MOR106
Why stopped
MOR106 clinical development in atopic dermatitis was stopped for futility
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-01-05